Scientists win award for Ebola antivirus
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 30/11/2017 (2896 days ago), so information in it may no longer be current.
Dr. Xiangguo Qiu and Dr. Gary Kobinger of the National Microbiology Lab in Winnipeg have won this year’s $100,000 Manning Innovation Principal Award for developing ZMapp, the world’s first Ebola disease antivirus.
“I am very honoured to be recognized for this award,” says Dr. Qiu.
“As a scientist, I feel very lucky to see that our persistent efforts have resulted in saving people’s lives.”
Qiu and Kobinger’s intellectual achievement spanned a decade’s search to find a treatment against the highly infectious and deadly Ebola virus infection.
The largest outbreak occurred from December 2013 to January 2016, when Ebola swept across West Africa, resulting in more than 28,000 cases and more than 11,000 deaths.
ZMapp was first used successfully for compassionate, emergency use in humans in July 2014.
It’s now the model driving the recent explosion of monoclonal antibody therapies against many other infectious agents such as HIV, Lassa, and Marburg among others.
They received the award at the 36th Manning Innovation Awards gala event at Toronto’s Scotiabank Centre on Wednesday night.